MedicalResearch.com |

Ravi Jayadevappa, PhD, MS Department of Medicine Perelman School of Medicine University of Pennsylvania Philadelphia, PA 19104-2676

15 Jul Prostate Cancer: Effects of Hormone Therapy on Cognitive Function Addressed in Large Study

Posted at 17:57h in Author Interviews, Cancer Research, Hormone Therapy, JAMA, Prostate Cancer, University of Pennsylvania

Our results suggest that clinicians need to carefully weigh the long-term risks and benefits of exposure to androgen deprivation therapy, particularly in patients with a long life expectancy or patients who already show signs of cognitive decline.

Ben Cordon, PhD NIHR Post-doctoral Academic Clinical Fellow Specialist Registrar training in cardiology

12 Jul Genetic Variants Linked to Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators

Posted at 12:11h in Author Interviews, Genetic Research, Heart Disease, Imperial College, JAMA

TTNtv genetic variants were associated with a 4.9-fold increased risk of receiving an appropriate ICD therapy

02 Jul Americans Support Gene Therapies Even If They Cost More

Posted at 05:16h in Author Interviews, Cost of Health Care, Genetic Research, Personalized Medicine

83% of Americans support efforts to advance the medical innovations offered by gene therapies.

Prof. Dr. med. Dirk Sibbing, MHBA, FESC Oberarzt, Medizinische Klinik und Poliklinik I Ludwig-Maximilians-Universität (LMU) München Chairperson ESC Working Group on Thrombosis München, Germany

11 Jun Updated Expert Consensus Statement on Platelet Function/Genetic Testing for Guiding P2Y12 Receptor-Inhibitor Treatment in PCI

Posted at 18:37h in Author Interviews, Clots - Coagulation, Heart Disease, JACC

According to large-scale trials and the respective guidelines, clopidogrel is the recommended P2Y12 inhibitor in stable patients, while prasugrel and ticagrelor are recommended, in the absence of contraindications, in patients with ACS.

Raymond H Mak, MDRadiation OncologyBrigham and Women's Hospital

19 Apr AI Poised to Revolutionize Radiation Therapy for Cancer

Posted at 12:42h in Author Interviews, Brigham & Women's - Harvard, Cancer Research, JAMA, Radiation Therapy, Technology

Applying crowd innovation to problems in healthcare can lead to rapid prototyping of AI solutions and catalyze transformations in healthcare delivery.

Dr. David Okonkwo, M.D., Ph.D., Professor of Neurological surgery Director of the Neurotrauma Clinical Trials CenterUniversity of Pittsburgh

18 Apr Stem Cell Therapy Improved Motor Deficit in Traumatic Brain Injury Trial

Posted at 12:04h in Author Interviews, Brain Injury, Stem Cells, Surgical Research, University of Pittsburgh

Stem cell therapy with SB623 cells in chronic TBI patients with fixed motor deficits achieved the primary efficacy endpoint of the Phase 2 clinical trial

H. Kirk Hammond, MDProfessor of Medicine at University of California, San DiegoBasic research scientist and cardiologistSan Diego Veterans' Affairs Healthcare System

28 Mar Gene Transfer Improved Cardiac Function in Diabetic Mouse Model

Posted at 14:46h in Author Interviews, Diabetes, Heart Disease, UCSD

The concept of a single administration of an agent that reduces blood sugar while increasing heart function, would be attractive to patients with diabete

Nancy Valente, M.D.VP of Global Hematology DevelopmentGenentech

25 Mar Genentech Submits New Drug Application to FDA for Venclexta Plus Gazyva for Untreated CLL with Co-Existing Medical Conditions

Posted at 18:01h in Author Interviews, Cancer Research, Genentech, Leukemia

These results indicate that Venclexta plus Gazyva could provide a chemotherapy-free, fixed-duration treatment option for people with previously untreated CLL with co-existing medical conditions.

Brian A Ference, MD, MPhil, MSc, FACC, FESCProfessor and Director of Research in Translational TherapeuticsExecutive Director, Centre for Naturally Randomized TrialsStrangeways Research LaboratoryUniversity of CambridgeCambridge, UK

13 Mar Genetic Evidence Suggests New LDL-C Lowering Drug May Decrease Cardiovascular Events and Have Additive Effect with Statins

Posted at 21:29h in Author Interviews, Genetic Research, Heart Disease, Lipids, NEJM, Statins

We found that lifelong exposure to lower LDL-C due to genetic inhibition of ATP-citrate lyase and HMG-CoA reductase were NOT associated with an increased risk of cancer.

Edward Kim, MD MSAssistant Professor of MedicineDivision of Rheumatology, Allergy and ImmunologyDirector, UNC Allergy and Immunology ClinicUniversity of North Carolina at Chapel HillChapel Hill, NC

04 Mar Egg Allergy: Oral Immunotherapy Has Potential for Lasting Benefit

Posted at 13:08h in Author Interviews, Immunotherapy

Egg egg oral immunotherapy has the potential to allow for introduction of egg products into the diet that can improve safety from allergic reactions and overall quality of life

Christopher R. Cederroth | Ph.D. Docent Associate Professor Experimental Audiology | Department of Physiology and Pharmacology Karolinska Institutet Sweden

21 Jan Tinnitus: Study of Adoptees Suggests Genetic Predisposition

Posted at 22:22h in Author Interviews, Genetic Research, Hearing Loss, JAMA, Karolinski Institute

MedicalResearch.com Interview with: Christopher R. Cederroth | Ph.D. Docent Associate Professor Experimental Audiology | Department of Physiology and Pharmacology Karolinska Institutet...

29 Nov Data Support National Guidelines for ARNI Therapy in Eligible Patients with Heart Failure with Reduced Ejection Fraction

Posted at 12:23h in Author Interviews, Blood Pressure - Hypertension, Heart Disease

MedicalResearch.com Interview with: Pratyaksh K. Srivastava, MD Division of General Internal Medicine, UCLA Gregg C. Fonarow, MD Ahmanson-UCLA Cardiomyopathy Center...

Dietmar P. Berger, MD, PhD Head of Global R&D Atara Biotherapeutic

27 Nov Multiple Sclerosis: T Cell Immunotherapy Targeting EBV Infected Cells Shows Promise

Posted at 18:57h in Author Interviews, Immunotherapy, Multiple Sclerosis

This study lends support to the EBV hypothesis in Multiple Sclerosis and suggests that a T cell immunotherapy targeting EBV infected B lymphocytes and plasma cells may be safe and have a positive effect on disease activity.

Ola Landgren, MD, PhD Professor of Medicine Chief, Myeloma Service Department of Medicine Memorial Sloan Kettering Cancer Center New York, NY 10065

26 Nov Second Generation 3-Drug Combination Found Safe & Effective for Newly Diagnosed Multiple Myeloma

Posted at 13:09h in Author Interviews, Cancer Research, JAMA

The second generation 3-drug combination KRd is safe and highly efficacious.

"JFK Plaza/ Breast Cancer Awareness" by nakashi is licensed under CC BY 2.0

10 Oct Breast Cancer: Gene Expression of Receptors on a Chip Can Enhance Precision Diagnosis

Posted at 14:24h in Author Interviews, Breast Cancer, Genetic Research

We have considered just two genes for each receptor. Many more genome data items would lend themselves to be included in the future

"All Ears..." by banlon1964 is licensed under CC BY-NC-ND 2.0

28 Sep Hyperbaric Oxygen Therapy Can Salvage Hearing In Some Sensorineural Loss Cases

Posted at 11:29h in Author Interviews, End of Life Care, Hearing Loss, JAMA

Hyperbaric oxygen therapy is basically a very safe and effective treatment with few side effects.

22 Sep High-Risk Gleason 5 Prostate Cancers Not Resistant to Androgen Deprivation Therapy

Posted at 12:01h in Author Interviews, Endocrinology, JAMA, Prostate Cancer, UCLA

MedicalResearch.com Interview with: Amar U. Kishan, MD Assistant Professor Department of Radiation Oncology University of California, Los Angeles MedicalResearch.com: What...

Dr Christina Elliott PhD Postdoctoral Researcher Department of Old Age Psychiatry King’s College London

20 Sep Amyloid Targeting Therapy More Likely To Be Effective Early in Alzheimer’s Disease

Posted at 17:30h in Alzheimer's - Dementia, Author Interviews

3. By identifying key molecules and signalling pathways underpinning Alzheimer’s Disease pathogenesis we may be able to identify drugs already in the clinic which may be repurposed.

Melanoma CDC/ Carl Washington, M.D., Emory Univ. School of Medicine; Mona Saraiya, MD, MPH

11 Sep IMPRES Score Predicts Melanoma Response to Immunotherapy

Posted at 22:49h in Author Interviews, Biomarkers, Cancer Research, Immunotherapy, Melanoma, Nature

IMPRES outperforms existing predictors for all treatment groups and captures almost all true responders while misclassifying less than half of the nonresponders

Prof Marco Falasca Head Metabolic Signalling Group School of Pharmacy & Biomedical Sciences | Faculty of Health Sciences Curtin University Western University

01 Aug Pancreatic Cancer: Cannabidiol + Chemotherapy Improved Survival (in mice)

Posted at 11:22h in Author Interviews, Cancer Research, Cannabis, Pancreatic

MedicalResearch.com Interview with: Prof Marco Falasca Head Metabolic Signalling Group School of Pharmacy & Biomedical Sciences Faculty of Health Sciences...

Arnab Chakravarti MD Professor and Chair of Radiation Oncology Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The Ohio State University Comprehensive Cancer Center

21 Jul Gene Biomarker Can Predict Brain Tumor Patients Who Have Better Outcomes

Posted at 00:01h in Author Interviews, Biomarkers, Brain Cancer - Brain Tumors, Cancer Research, Genetic Research

MedicalResearch.com Interview with: Arnab Chakravarti MD Professor and Chair of Radiation Oncology Arthur G. James Cancer Hospital and Richard J....

Ashani Weeraratna, Ph.D. The Ira Brind professor and Co-program leader of the Immunology, Microenvironment and Metastasis Program The Wistar Institute Member of Wistar’s Melanoma Research Center Philadelphia

21 Jun Anti-PD1 Immunotherapy May Work Better in Older Melanoma Patients

Posted at 20:15h in AACR, Aging, Author Interviews, Cancer Research, Immunotherapy, Melanoma

Ashani Weeraratna, Ph.D. The Ira Brind professor and Co-program leader of the Immunology, Microenvironment and Metastasis Program The Wistar Institute Member of Wistar’s Melanoma Research Center Philadelphia MedicalResearch.com: What is the background for this study? What are the main findings? Response: This study shows for the first time that older patients, especially those who have had prior MAPKi therapy fare better than younger patients when treated with anti-PD1. We found that tumors in younger patients and younger mice have higher levels of Tregulatory cells, the cells that regulate other immune cells. This is not true systemically, only within the tumor microenvironment. We were surprised because we expected that, as with targeted therapy, older patients would have a poorer response to immunotherapy, given what we perceive as a poorer immune system in older patients.

16 Jun Synovial tissue profiling in autoantibody positive at risk individuals reveals gene signatures associated with later development of rheumatoid arthritis

Posted at 21:15h in Author Interviews, Biomarkers, Rheumatology

MedicalResearch.com Interview with: Dr. Lisa van Baarsen PhD Principal Investigator at the Amsterdam Rheumatology and Immunology Cente Academic Medical Center...

05 Jun Everolimus Plus Exemestane vs Monotherapy for ER+ HER2- Advanced Breast Cancer

Posted at 00:49h in Author Interviews, Breast Cancer, Chemotherapy, JAMA

MedicalResearch.com Interview with: Dr. Guy Jerusalem, MD, PhD CHU Sart Tilman Liege and Liege University Liege, Belgium MedicalResearch.com: What is the background...

29 May SUNSET Trial Supports Bronchodilators as Foundation of COPD Therapy

Posted at 23:37h in Author Interviews, Pulmonary Disease

MedicalResearch.com Interview with: Kenneth R. Chapman, MD MSc FRCPC FACP FCCP, FERS Director, Asthma & Airway Centre, University Health Network,...

18 Apr Chemotherapy Choice Can Be Aided By Assessing TDP Profile

Posted at 11:23h in AACR, Author Interviews, Genetic Research

MedicalResearch.com Interview with: Ed Liu, M.D President and CEO The Jackson Laboratory (JAX) MedicalResearch.com: What is the background for this...

26 Mar Everolimus plus Endocrine Therapy: Effective 1st Line Option for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer

Posted at 23:48h in Author Interviews, Breast Cancer, Chemotherapy, JAMA, Novartis

MedicalResearch.com Interview with: Melanie E. Royce, MD, PhD Division of Hematology/Oncology University of New Mexico Comprehensive Cancer Center Albuquerque MedicalResearch.com: What is the background...

22 Mar Obesity Fuels Resistance To Anti-VEGF Therapy in Breast Cancer Patients

Posted at 15:35h in Author Interviews, Breast Cancer, Brigham & Women's - Harvard, Science, Weight Research

MedicalResearch.com Interview with: Dai Fukumura, M.D., Ph.D Associate Professor, Radiation Oncology Harvard Medical School Deputy Director, Edwin L. Steele Laboratory,...

26 Feb Genetic Variant of p53 Associated With Poor Breast Cancer Survival

Posted at 23:18h in Author Interviews, Biomarkers, Breast Cancer, Cancer Research, Genetic Research

MedicalResearch.com Interview with: Maureen E. Murphy, Ph.D. Program Leader and Professor Molecular and Cellular Oncogenesis and Subhasree Basu PhD Postdoctoral...

06 Feb ASPIRE: Combination Therapy With KYPROLIS (carfilzomib) Extended Overall Survival in Relapsed/Refractory Multiple Myeloma

Posted at 17:57h in Author Interviews, Cancer Research, Chemotherapy, Journal Clinical Oncology

MedicalResearch.com Interview with: David S. Siegel, MD, PhD Chief, Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack,...